Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Great presentation in Oncology
View:
Post by palinc2000 on Nov 11, 2021 10:05am

Great presentation in Oncology

Paul s best delivery so far
Comment by Wino115 on Nov 11, 2021 10:13am
Need to look at that slide again but appears they are now up to that 2x normal dosage level (420) after the SAE 2 and need to get 3 patients at that level with no DLT to move to the next one that is 30% more drug.  It seems they've gotten there with minimal patients (9) which while that sounds slow, actually means they've been able to move up each level with just one patient because ...more  
Comment by Wino115 on Nov 11, 2021 10:15am
No free docetaxol - seeing the same in humans as we say in preclinical.  There's that very clear statement. 
Comment by canadapiet on Nov 11, 2021 10:26am
It should also be a great indication that those very serious ill patients are still on the trial, indicating that there must be some "life extending medication" ..........isn't it????? Hope Wino115 - (11/11/2021 10:15:53 AM)  RE:RE:Great presentation in Oncology No free docetaxol - seeing the same in humans as we say in preclinical.  There's that very clear ...more  
Comment by palinc2000 on Nov 11, 2021 10:36am
I think Recruted  patients must have a life expectancy of at least 3 mos ...So I dont think this is a foregone conclusion,Not must but maybe could
Comment by palinc2000 on Nov 11, 2021 10:26am
This is what I heard also!!! It is now a Fact!!!!
Comment by Wino115 on Nov 11, 2021 10:36am
Yes, but only that fact surrounding them not seeing the drug accumulating in the patients blood plasma.  So it seems to indicate off-target drug release is very low (1 fact we need to account for now) and that the PDC is not degrading in the bloodstream so is going somewhere to release that drug (2nd fact we need to account for now).  My unscientific mind says this may not preclude one ...more  
Comment by jfm1330 on Nov 11, 2021 1:01pm
Not listened to the presentation yet, but what you say below is impossible. Docetaxel is eliminated through the liver, by-products goes in the bile, and finally in the feces. Very little goes in the urine.
Comment by SPCEO1 on Nov 11, 2021 10:58am
When I saw that slide, it did not seem to indicate whether it was from pre-clinical or from the phase 1a. I figured it was pre-clinical but thought I should ask to be sure and I am sure glad I did! But why wouldn't that info be something they would be anxcious to share with us??? I should not have had to ask about it. What is the point is holding back such info? And what else could they share ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities